Study S001413

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

ClinicalTrials.gov record

Registration

Registration: NCT06828055
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 280
Start: 2024-12-18
Primary completion: 2025-06-24
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss
Interventions: DRUG:Placebo; DRUG:VK2735
Results posted: FALSE

Registered primary outcomes

Percent (relative) change from baseline in body weight after 13 weeks of treatment [13 Weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.